Phyllanthus niruri Linn increase infiltrating lymphocyte and apoptosis of rectosigmoid cancer patients. A phase II clinical trial

Riwanto, Ignatius; Budiono, Parish; Mughni, Abdul; Martahadinan, Martahadinan; Putra, Nugrahanta Dasa; Mambu, Toar; Sayuti, Mochamad

doi:10.15562/bmj.v6i3.674

Bali Med J.

2017

DOI: 10.15562/bmj.v6i3.674

|View full text |Cite

Phyllanthus niruri Linn increase infiltrating lymphocyte and apoptosis of rectosigmoid cancer patients. A phase II clinical trial

Ignatius Riwanto

Parish Budiono

Abdul Mughni

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2022

2023

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Phase II clinical trials have also been conducted on people with rectum cancer, where the results of clinical trial II showed the extract. Phyllanthus urnaria can significantly increase cancer cell apoptosis and expression of lymphocytes, perforins, granzymes, and caspase 3 that infiltrate significantly [38].…”

mentioning

confidence: 99%

Expression of IL-17 on Breast Cancer Mice Treated by Combination of Phyllanthus Urinaria and Catharanthus roseus Extract

Shofiyah

Djati

Rifa’i

2022

JELS

View full text Add to dashboard Cite

This study aimed to evaluate the effect of combination Phyllanthus urinaria and Catharanthus roseus in breast cancer mice based on the expression of anthracene (DMBA) was injected intraperitoneally into normal mice at dose 1.5 mg.kg -1 weight to obtain breast cancer mice. Total of 24 experimental mice divided into normal mice (N), breast cancer mice (K), breast cancer mice with cisplatin (C) treatment (5 mg.kg -1 weight), breast cancer mice with combination extract Dose 1 (P. urinaria 500 mg.kg -1 weigt + C. roseus 15mg.kg -1 weight), breast cancer mice with combination extract Dose 2 (P. urinaria 1000 mg.kg -1 weight + C. roseus 75mg.kg -1 weight), and breast cancer with combination extract Dose 3 (P. urinaria 2000 mg.kg -1 weight + C. roseus 375 mg.kg -1 weight). Cheral was given orally for 14 days. The level of IL-17 was evaluated by flow cytometry analysis. The combination can suppress the expression of IL-17 which down regulation of IL-17 indicate a good prognosis for the breast cancer mice, for 6.17% in breast cancer condition to 0.93% with Dose 3 treatment. The combination can be used as immunomodulatory agent in humoral immunity through the regulation of IL-17.

show abstract

mentioning

confidence: 99%

Expression of IL-17 on Breast Cancer Mice Treated by Combination of Phyllanthus Urinaria and Catharanthus roseus Extract

Shofiyah

Djati

Rifa’i

2022

JELS

View full text Add to dashboard Cite

show abstract

In-Silico Prediction of Phytoconstituents from Phyllanthus niruri for Anticancer Activity against Prostate Cancer Targeting MRCK kinases

P. Motghare,

P. Katolkar,

S. Lichade

2023

RJPT

View full text Add to dashboard Cite

Objective: Prostate cancer is a disease in which the malignant cells form in the tissues of the prostate. Once more, medicinal plants are being researched for the treatment of lung cancer. Prototypical compounds found in medicinal plants have been the source of many conventional medications. In-silico testing of Phyllanthus niruri phytoconstituents for anticancer efficacy was a part of our investigation. Design: Utilizing Discovery studio, molecular docking is done to assess the pattern of interaction between the phytoconstituents from the Phyllanthus niruri plant and the crystal structure of the anticancer proteins (PDB ID: 5OTE). Later, SwissADME and pkCSM were used to screen for toxicity as well as the pharmacokinetic profile. Results: The docked results suggest that luteolin (-8.2kcal/mol), and caffeic acid (-6.5kcal/mol), for 5OTE macromolecule has best binding affinity towards MRCK for anticancer activity on prostate as compared to the standard drug lenvatinib mesylate (-3.4kcal/mol). Furthermore, pharmacokinetics and toxicity parameters were within acceptable limits according to ADMET studies. Conclusion: Results from the binding potential of phytoconstituents aimed at anticancer activity were encouraging. It promotes the usage of Phyllanthus niruri and offers crucial details on pharmaceutical research and clinical care.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Phyllanthus niruri Linn increase infiltrating lymphocyte and apoptosis of rectosigmoid cancer patients. A phase II clinical trial

Cited by 2 publications

References 0 publications

Expression of IL-17 on Breast Cancer Mice Treated by Combination of Phyllanthus Urinaria and Catharanthus roseus Extract

Expression of IL-17 on Breast Cancer Mice Treated by Combination of Phyllanthus Urinaria and Catharanthus roseus Extract

In-Silico Prediction of Phytoconstituents from Phyllanthus niruri for Anticancer Activity against Prostate Cancer Targeting MRCK kinases

Contact Info

Product

Resources

About